Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • Trump Accounts — What Families Need to Know in 2026

    As of March 2026, full guidance has not been released and details/implementation strategy may be subject to change.

    Read more

  • The Multi-Billion Dollar Price Tag of U.S. Rare Earth Independence

    As geopolitical risks rise, the U.S. is pouring capital into building a domestic rare earth supply chain—an effort with massive costs, tight timelines, and significant investment implications.

    Read more

  • Economics Weekly: Wobbles in Private Debt Market

    One topic we have increasingly been receiving questions on over the last few weeks has been private credit, and in this Economics Weekly, we address concerns about whether recent emerging issues in the space pose a systemic threat to the banking system and the wider economy.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures